BAMF Health and Corewell Health Haworth Innovative Therapeutics Clinic plan to collaborate on a clinical trial to test targeted radiation therapy for cancer patients.
The phase I trial is sponsored by Y-mAbs Therapeutics and will include both adolescent and adult patients with recurrent or resistant small-cell lung cancer, sarcoma, and malignant melanoma. Trial participants will receive tumor-targeting treatment with an antibody that binds to a protein called GD-2 on the surface of the cancer cells, then a radioisotope infusion that binds to the antibody and delivers the radiation to cancer cells, BAMF Health said.
